Edwards Lifesciences Corporation $EW Stock: Robeco Schweiz AG Boosts Stake

Robeco Schweiz AG grew its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 79.9% in the third quarter, Holdings Channel reports. The fund owned 29,742 shares of the medical research company’s stock after buying an additional 13,213 shares during the quarter. Robeco Schweiz AG’s holdings in Edwards Lifesciences were worth $2,567,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Pin Oak Investment Advisors Inc. bought a new stake in Edwards Lifesciences in the second quarter worth $26,000. TrinityBridge Ltd purchased a new stake in Edwards Lifesciences during the second quarter valued at $27,000. GK Wealth Management LLC bought a new position in Edwards Lifesciences during the third quarter valued at $26,000. RMG Wealth Management LLC bought a new position in Edwards Lifesciences during the first quarter valued at $26,000. Finally, Compass Financial Management LLC bought a new position in Edwards Lifesciences during the second quarter valued at $32,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Up 0.1%

NYSE:EW opened at $89.15 on Monday. The company has a market cap of $51.33 billion, a price-to-earnings ratio of 51.23, a price-to-earnings-growth ratio of 2.33 and a beta of 0.87. Edwards Lifesciences Corporation has a twelve month low of $74.66 and a twelve month high of $96.29. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The stock has a fifty day simple moving average of $88.05 and a 200-day simple moving average of $86.65.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.67 earnings per share. Analysts anticipate that Edwards Lifesciences Corporation will post 3.00 EPS for the current year.

Insider Activity at Edwards Lifesciences

In related news, VP Daniel Lippis sold 619 shares of Edwards Lifesciences stock in a transaction dated Thursday, October 8th. The shares were sold at an average price of $85.65, for a total transaction of $53,017.35. Following the completion of the sale, the vice president owned 40,034 shares in the company, valued at $3,428,912.10. This trade represents a 1.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Annette Brüls sold 2,644 shares of the business’s stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $89.98, for a total transaction of $237,907.12. Following the completion of the sale, the vice president directly owned 17,984 shares of the company’s stock, valued at approximately $1,618,200.32. This trade represents a 12.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 5,045 shares of company stock worth $451,596 in the last 90 days. 0.31% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Mizuho lifted their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 15th. Argus upped their target price on shares of Edwards Lifesciences from $105.00 to $115.00 and gave the company a “buy” rating in a research report on Friday, August 21st. Robert W. Baird decreased their target price on shares of Edwards Lifesciences from $94.00 to $90.00 and set a “neutral” rating on the stock in a research report on Thursday, October 15th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a report on Thursday, October 15th. Finally, Evercore reiterated an “outperform” rating on shares of Edwards Lifesciences in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $100.27.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.